Cambrex Co. (NYSE:CBM) Receives $52.40 Average PT from Brokerages

Cambrex Co. (NYSE:CBM) has been given a consensus recommendation of “Hold” by the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $52.40.

CBM has been the topic of a number of recent analyst reports. William Blair lowered shares of Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price target on the stock. in a research note on Wednesday, August 7th. Craig Hallum lowered shares of Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target on the stock. in a research note on Monday, August 12th. Zacks Investment Research lowered shares of Cambrex from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Finally, ValuEngine lowered shares of Cambrex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Cambrex by 2.7% in the second quarter. BlackRock Inc. now owns 5,001,164 shares of the biotechnology company’s stock worth $234,103,000 after acquiring an additional 132,617 shares during the period. Vanguard Group Inc. increased its stake in shares of Cambrex by 1.2% in the second quarter. Vanguard Group Inc. now owns 3,504,246 shares of the biotechnology company’s stock worth $164,034,000 after acquiring an additional 42,200 shares during the period. Clearbridge Investments LLC boosted its holdings in Cambrex by 0.3% during the first quarter. Clearbridge Investments LLC now owns 1,337,800 shares of the biotechnology company’s stock worth $51,974,000 after buying an additional 3,589 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Cambrex by 16.8% during the first quarter. Lazard Asset Management LLC now owns 924,844 shares of the biotechnology company’s stock worth $35,930,000 after buying an additional 133,133 shares in the last quarter. Finally, American Capital Management Inc. boosted its holdings in Cambrex by 14.3% during the first quarter. American Capital Management Inc. now owns 764,238 shares of the biotechnology company’s stock worth $29,691,000 after buying an additional 95,441 shares in the last quarter.

Cambrex stock traded down $0.02 during mid-day trading on Friday, reaching $59.57. 19,711 shares of the company traded hands, compared to its average volume of 456,165. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.44 and a quick ratio of 1.77. Cambrex has a fifty-two week low of $33.80 and a fifty-two week high of $63.36. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 21.50, a price-to-earnings-growth ratio of 4.66 and a beta of 2.19. The firm’s fifty day moving average is $59.62 and its two-hundred day moving average is $47.87.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Read More: What does a bar chart display?

Analyst Recommendations for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.